SNDX: Syndax Pharmaceuticals Inc Company Profile & Statistics

About

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Info & Links

CEO

Michael A. Metzger

Headquarters

35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM, MA 02451, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

Employees

184

Syndax Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization²

1.11B

Enterprise Value

981.79M

Enterprise Value/EBITDA(ttm)

-2.93

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

3.04

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

Profit Margin(ttm)

-654.42%

Return on Equity(ttm)

-64.34%

Return on Invested Capital(ttm)

-66.42%

Return on Assets(ttm)

-57.72%

Income Statement

Revenue(ttm)

16.00M

Revenue Per Share(ttm)

0.19

Gross Profit(ttm)

16.00M

EBITDA(ttm)³

-335.19M

Net Income Available to Common(ttm)

-297.06M

Diluted EPS(ttm)

-3.63

Share Statistics

Beta (5Y Monthly)

0.89

52-Week Change

-21.80%

S&P 500 52-Week Change

25.43%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

85.36M

Dividend Yield

0.00%

Float⁴

81.86M

% Held by Insiders

4.10%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

406.39M

Total Cash Per Share(mrq)

4.76

Total Debt(mrq)

12.00K

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.99%

Quick Ratio(mrq)

6.99%

Book Value Per Share(mrq)

4.28

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.55

Free Cash Flow(ytd)

-217.51M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SNDX

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc Profile